Prometheus Rebound: Where Weak Patents Can Benefit Pharma
This article was originally published in RPM Report
Executive Summary
Biotech and pharma companies were disappointed when the Supreme Court limited patent rights surrounding personalized medicine. But the ruling may end up simplifying the path to adoption of targeted therapies by reaffirming a much more critical point: the therapeutic—not the diagnostic—is the dominant partner.